TEL AVIV, Israel, June 03, 2020 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced the pricing of an underwritten […]
Tag: InspireMD
InspireMD Announces First Quarter 2020 Financial Results
First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major markets Management to host investor conference call today, May 12, at 8:30am ET TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) […]
InspireMD Announces Fourth Quarter and Year-End 2019 Financial Results
Robust CGuard™ EPS year-over-year revenue growth of 31% Management to host investor conference call today, March 10, at 8:30am ET TEL AVIV, Israel, March 10, 2020 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) […]
InspireMD Announces Planned Leadership Transition
Life sciences industry veteran Marvin Slosman appointed Chief Executive Officer Appointment adds significant medical technology commercialization experience to the InspireMD team TEL AVIV, Israel, Dec. 10, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ […]
InspireMD Reports Updated Positive CGuard™ EPS Data Presented at VEITH 2019
CGuard™ EPS clinical data featured as a prominent discussion point in multiple key presentations Data from investigator-initiated multicenter, 729-patient IRONGUARD 2 study suggests that the use of CGuard™ EPS in routine clinical practice is associated with no major periprocedural, 30-day […]
UPDATE: InspireMD Announces Third Quarter 2019 Financial Results
Strong revenue driven by record orders of CGuard™ EPS Management to host investor conference call today, November 12, at 8:30am ET TEL AVIV, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention […]
InspireMD, Inc. Announces Pricing of $5 Million Underwritten Public Offering
TEL AVIV, Israel, Sept. 19, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced the pricing of an underwritten public offering […]
InspireMD Provides Business Update
TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today provided a business update. Positive CGuard™ […]
InspireMD Announces First Quarter 2019 Financial Results
TEL AVIV, Israel, May 14, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the […]
InspireMD, Inc. Announces Pricing of $2.4 Million Public Offering of Common Stock
Email Print Friendly Share April 04, 2019 06:00 ET | Source: InspireMD, Inc. TEL AVIV, Israel, April 04, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of […]
